Bellerophon Therapeutics

Hampton, United States Founded: 2014 • Age: 12 yrs Listed
Drug-device therapies for pulmonary hypertension are developed.

About Bellerophon Therapeutics

Bellerophon Therapeutics is a publicly listed company based in Hampton (United States) founded in 2014. Drug-device therapies for pulmonary hypertension are developed. The company has 18 employees. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Aria CV, Adient Medical and Crux Biomedical; 3 of its 3 listed competitors have raised funding.

Company details

Bellerophon Therapeutics is a clinical-stage biotherapeutics company developing products to treat cardiopulmonary and cardiac diseases. Its product, the INOpulse is a combination drug-device therapy that they are developing for the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF). The device delivers Nitrous Oxide, a vasodilator into the pulmonary blood vessels, thus dilating them. The company spun out from Ikaria in 2014. Its key products include a nitric oxide delivery device and a bio-absorbable cardiac matrix. Both products are still in development. The company went public in Feb 2015.

  • Headquarters Hampton, United States
  • Employees 18
  • Stage Public
  • Sectors
    Healthcare
  • Website bellerophon.com
  • Social LinkedIn
Key Metrics
  • Net Profit
    -$19.83 M (USD)
    -12
    as on Dec 31, 2022
  • EBITDA
    -$22.38 M (USD)
    -11
    as on Dec 31, 2022
  • Latest Funding Round
    $23.44M (USD), Post-IPO

    Oct 2017

  • Investors
  • Employee Count
    18

Funding Insights of Bellerophon Therapeutics

  • Total Rounds 2
  • Last Round Post-IPO — $23.44M
  • First Round $23M

    (Sep 2017)

  • Investors Count 4

All 2 funding rounds of Bellerophon Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2017$23.44MPost-IPO––
–
Sep 2017$23MPost-IPO––
Valuation history

4 investors in total: 4 institutional.

Investors in Bellerophon Therapeutics

Bellerophon Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Linde Group, Puissance Capital and New Mountain Capital.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
New Mountain Capital manages investments in private equity, credit, and net lease strategies.
newmountaincapital.com
VC & PE firm focused on healthcare sector
venrockcp.comPalo Alto, United States
Manages diversified investment portfolios across multiple asset classes.
2015puissancecapital.comNew York, United States
Industrial, process, and specialty gases are supplied to various sectors.
1880lindeus.comUnited States
Premium access

Investor details for Bellerophon Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Bellerophon Therapeutics

1 people are tracked at Bellerophon Therapeutics (1 in team); the tracked headcount is 18.

NameRoleGroup
Manfred Hanuschek
Financial ConsultantTeam
Premium access

Complete people profiles for Bellerophon Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Bellerophon Therapeutics

4 dated milestones of Bellerophon Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Bellerophon Therapeutics is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $23.0M.
  4. Funding Latest funding round, Post-IPO, of $23.4M.

Competitors of Bellerophon Therapeutics

Bellerophon Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Aria CV, Adient Medical and Crux Biomedical.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
ariacv.com2010Saint Paul, United States$44.98M17
Device for pulmonary hypertension
adientmedical.com2012Pearland, United States$19.43M6,421
Bioabsorbable medical devices are developed for pulmonary embolism prevention.
cruxbiomedical.com2004Menlo Park, United States$8M
Retrievable vena cava filters are developed to prevent pulmonary emboli.
Premium access

Detailed competitors of Bellerophon Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Cardiac and Vascular Disorders

3 companies that operate in the same segment as Bellerophon Therapeutics (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Gene-editing therapies for coronary artery disease are developed.
2018Cambridge, Massachusetts, United StatesUSD 215.5 M255
Cardiac monitoring devices and applications are provided for heart health.
2010Mountain View, California, United StatesUSD 114.38 MUSD 6.18 M67
Therapies for lowering low-density lipoprotein cholesterol levels are developed.
1998Ann Arbor, Michigan, United StatesUSD 129.7 MUSD 332.31 M304
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Bellerophon Therapeutics

Premium access

Complete news archive for Bellerophon Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bellerophon Therapeutics

Bellerophon Therapeutics was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Bellerophon Therapeutics is headquartered in Hampton, United States. It is registered at Hampton, Virginia, United States.

Bellerophon Therapeutics has 18 employees.

Bellerophon Therapeutics is a clinical-stage biotherapeutics company developing products to treat cardiopulmonary and cardiac diseases. Its product, the INOpulse is a combination drug-device therapy that they are developing for the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF). The device delivers Nitrous Oxide, a vasodilator into the pulmonary blood vessels, thus dilating them. The company spun out from Ikaria in 2014. Its key products include a nitric oxide delivery device and a bio-absorbable cardiac matrix. Both products are still in development. The company went public in Feb 2015.

Bellerophon Therapeutics's top competitors include Aria CV, Adient Medical and Crux Biomedical.

Bellerophon Therapeutics has 4 investors. Key investors include Linde Group, Puissance Capital, New Mountain Capital, and Venrock Capital Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available